• Sumatriptan as an Anti-Inflammatory: Evidence Beyond Migrain

  2026-06-20

  This systematic review systematically evaluates the anti-inflammatory actions of sumatriptan, a 5-HT1B/1D receptor agonist long used for migraine. Key findings reveal that sumatriptan modulates cytokine release and nitric oxide pathways, suggesting repositioning opportunities for inflammatory conditions.

• RG7388: Advancing MDM2 Antagonist Strategies for Synergistic

  2026-06-19

  Explore how RG7388, a potent MDM2 antagonist, enables advanced strategies for p53 pathway activation and synergistic cancer therapy. This article uniquely bridges mechanistic insights with practical assay and combination protocol guidance.

• Rotavirus Infection Disrupts Nrf2-Driven Redox Defense Pathw

  2026-06-19

  This study demonstrates that progressive rotavirus infection leads to marked downregulation of the redox-sensitive transcription factor Nrf2 and its target genes, despite initial induction during early oxidative stress. The findings clarify mechanisms of viral interference with cellular antioxidant defenses and highlight the complexity of Nrf2 regulation during infection, with implications for antiviral research and therapeutic targeting.

• Intravesical p21 mRNA-LNP Therapy for Bladder Cancer: Mechan

  2026-06-18

  This article critically reviews recent evidence for intravesical delivery of p21 mRNA–loaded lipid nanoparticles as a tumor suppressor replacement therapy in non–muscle-invasive bladder cancer. The study establishes a mechanistically grounded, localized mRNA therapy approach that suppresses tumor growth and restores p21 expression, with practical implications for translational oncology.

• Thymoquinone in Cardiotoxicity: Mechanisms and Translational

  2026-06-18

  This article explores thymoquinone's mechanistic role as a small-molecule probe in the mitigation of doxorubicin-induced cardiotoxicity, outlining key experimental insights, protocol guidance, and its broader translational implications. With a focus on advanced pathway modulation—including VEGFR2–PI3K–Akt axis inhibition, STAT3 suppression, and anti-ferroptotic effects—this thought leadership piece provides strategic direction for researchers pushing the boundaries of cardioprotection and oxidative stress modeling.

• DEGS2 Drives Prostate Cancer Stemness via PI3K-AKT and Phyto

  2026-06-17

  This study reveals that upregulation of DEGS2 and its product phytoceramide enhances prostate cancer stem-like properties through PI3K-AKT signaling. The findings identify DEGS2 as a key metabolic regulator of cancer stemness, offering new avenues for targeted intervention in castration-resistant prostate cancer.

• H 89 2HCl: Precision PKA Inhibition for Circuit-Level Neuros

  2026-06-17

  Discover how H 89 2HCl enables targeted dissection of cAMP/PKA signaling in neural circuits. By integrating selective kinase inhibition with circuit-level insights, this article explores advanced applications beyond standard PKA pathway studies.

• Epoxomicin: Precision Proteasome Inhibition for Pathway Rese

  2026-06-16

  Epoxomicin stands out as a highly selective, irreversible proteasome inhibitor for dissecting ubiquitin-proteasome pathway dynamics—enabling robust assays in protein degradation, inflammation, and disease modeling. This article unpacks advanced workflows, troubleshooting insights, and the translational impact of Epoxomicin, drawing from cutting-edge studies and best practices.

• Mitomycin C: Mechanistic Depth and Innovation in Cancer Rese

  2026-06-16

  Explore the advanced mechanisms and unique research applications of Mitomycin C, a potent antitumor antibiotic. This article delivers a scientifically rigorous, in-depth perspective on DNA replication inhibition and apoptosis signaling, offering new insights for translational cancer research.

• 20-HETE, TRPV1, and MrgprA3+ Neurons in Chronic Dermatitis I

  2026-06-15

  This study uncovers how the arachidonic acid metabolite 20-HETE activates TRPV1 channels on sensitized MrgprA3+ neurons, driving allokinetic itch in chronic dermatitis. Through advanced mouse models and targeted pharmacology, the work clarifies the neural and molecular interplay between pain and itch, highlighting new intervention points for chronic itch syndromes.

• Norovirus Exploits NINJ1 for Selective NS1 Protein Secretion

  2026-06-15

  Song et al. reveal that murine norovirus hijacks NINJ1, a key executor of plasma membrane rupture, to selectively secrete the viral protein NS1 during infection. This study uncovers a previously unrecognized, highly regulated mechanism of protein secretion, providing new insights into viral immune evasion and the broader control of damage-associated molecular patterns (DAMPs) release.

• Red Blood Cell Lysis Buffer: Enabling High-Fidelity Hematolo

  2026-06-14

  Explore how Red Blood Cell Lysis Buffer (erythrocyte lysis buffer) empowers precise blood sample preparation, preserves nucleated cells, and advances both hematological and osteogenic research. Learn how this approach uniquely bridges immunological workflows with emerging bone biology insights.

• Technical Use of 0.4% Trypan Blue Solution for Cell Viabilit

  2026-06-13

  0.4% Trypan Blue Solution addresses the need for rapid, exclusion-based live/dead cell discrimination in cell culture and cytotoxicity assays. It is optimized for membrane-integrity–based cell viability measurement in research workflows, but is not suitable for diagnostic or clinical applications.

• Tetracycline in Research: Optimizing Selection and Ribosomal

  2026-06-12

  Tetracycline stands out as a broad-spectrum polyketide antibiotic for both antimicrobial selection and advanced ribosomal function research, thanks to its reversible binding and reliable performance. This guide delivers actionable protocols, troubleshooting insights, and direct workflows for maximizing reproducibility—backed by current literature and recent breakthroughs in cellular senescence modeling.

• Antiarrhythmic Drug Effects on KCa2 Channels in AF: Evidence

  2026-06-12

  This study systematically evaluated whether widely used antiarrhythmic agents—including Dronedarone (Multaq)—directly inhibit small conductance calcium-activated potassium (KCa2.X) channels, a promising atrial-selective target for atrial fibrillation (AF) treatment. The findings reveal that most clinically recommended drugs, including Dronedarone, do not significantly inhibit KCa2.X channels at therapeutic concentrations, clarifying their mechanisms of action and informing future research directions.

466 records 15/32 page Previous Next First page 上5页 1112131415 下5页 Last page